Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Stanford, CA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Denver, CO
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Washington,
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Miami, FL
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Orlando, FL
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Tallahassee, FL
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Tampa, FL
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Atlanta, GA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Augusta, GA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Lexington, KY
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
St. Paul, MN
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
St. Paul, MN
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Columbia, MO
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Columbia, MO
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Kansas City, MO
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Cherry Hill, NJ
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Buffalo, NY
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Mineola, NY
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Syracuse, NY
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Raleigh, NC
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Akron, OH
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Cleveland, OH
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Columbus, OH
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Portland, OR
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Morristown, TN
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Morristown, TN
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Nashville, TN
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Dallas, TX
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Houston, TX
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Charlottesville, VA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Norfolk, VA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Richmond, VA
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Capital Federal,
Pediatric Epilepsy Study in Subjects 1-24 Months
An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Capital Federal,
Click here to add this to my saved trials
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy
Clinical Outcomes Validation in Non Ambulatory and Young Boys/Men With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated:  1/17/2017
Washington University
mi
from
St. Louis, MO
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy
Clinical Outcomes Validation in Non Ambulatory and Young Boys/Men With Duchenne Muscular Dystrophy (DMD)
Status: Enrolling
Updated: 1/17/2017
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
University of California at San Francisco
mi
from
San Francisco, CA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Connecticut Clinical Research
mi
from
Cromwell, CT
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Connecticut Clinical Research
mi
from
Cromwell, CT
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Miami Research Associates
mi
from
South Miami, FL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Kennedy Krieger Institute
mi
from
Baltimore, MD
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Neuro-Behavioral Clinical Research, Inc.
mi
from
Canton, OH
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Neuro-Behavioral Clinical Research, Inc.
mi
from
Canton, OH
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Suburban Research Associates
mi
from
Media, PA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Click here to add this to my saved trials